1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis.

BACKGROUND AND OBJECTIVES Elevated serum vitamin D with hypercalciuria can result in nephrocalcinosis and nephrolithiasis. This study evaluated the cause of excess 1,25-dihydroxycholecalciferol (1α,25(OH)2D3) in the development of those disorders in two individuals. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS Two patients with elevated vitamin D levels and nephrocalcinosis or nephrolithiasis were investigated at the National Institutes of Health (NIH) Clinical Center and the NIH Undiagnosed Diseases Program, by measuring calcium, phosphate, and vitamin D metabolites, and by performing CYP24A1 mutation analysis. RESULTS Both patients exhibited hypercalciuria, hypercalcemia, low parathyroid hormone, elevated vitamin D (1α,25(OH)2D3), normal 25-OHD3, decreased 24,25(OH)2D, and undetectable activity of 1,25(OH)2D-24-hydroxylase (CYP24A1), the enzyme that inactivates 1α,25(OH)2D3. Both patients had bi-allelic mutations in CYP24A1 leading to loss of function of this enzyme. On the basis of dbSNP data, the frequency of predicted deleterious bi-allelic CYP24A1 variants in the general population is estimated to be as high as 4%-20%. CONCLUSIONS The results of this study show that 1,25(OH)2D-24-hydroxylase deficiency due to bi-allelic mutations in CYP24A1 causes elevated serum vitamin D, hypercalciuria, nephrocalcinosis, and renal stones.

[1]  Glenville Jones,et al.  25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. , 2012, Archives of biochemistry and biophysics.

[2]  Dawn S Milliner,et al.  Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. , 2012, The Journal of clinical endocrinology and metabolism.

[3]  L. Nieman,et al.  Prolonged remission after long-term treatment with steroidogenesis inhibitors in Cushing's syndrome caused by ectopic ACTH secretion. , 2012, European journal of endocrinology.

[4]  T. Carpenter.  Take another CYP: confirming a novel mechanism for "idiopathic" hypercalcemia. , 2012, The Journal of clinical endocrinology and metabolism.

[5]  J. Hirschhorn,et al.  Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. , 2012, The Journal of clinical endocrinology and metabolism.

[6]  B. Hoppe,et al.  Nephrocalcinosis and urolithiasis in children. , 2011, Kidney international.

[7]  E. Streeten,et al.  CYP24A1 mutations in idiopathic infantile hypercalcemia. , 2011, The New England journal of medicine.

[8]  Rena A. Godfrey,et al.  The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases , 2011, Genetics in Medicine.

[9]  Frederick G. Strathmann,et al.  Quantification of 1α,25-dihydroxy vitamin D by immunoextraction and liquid chromatography-tandem mass spectrometry. , 2011, Clinical chemistry.

[10]  M. Konrad,et al.  Mutations in CYP24A1 and idiopathic infantile hypercalcemia. , 2011, The New England journal of medicine.

[11]  David J. Sas.  An update on the changing epidemiology and metabolic risk factors in pediatric kidney stone disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[12]  Glenville Jones,et al.  Bioengineering Anabolic Vitamin D-25-Hydroxylase Activity into the Human Vitamin D Catabolic Enzyme, Cytochrome P450 CYP24A1, by a V391L Mutation* , 2011, The Journal of Biological Chemistry.

[13]  J. Mullikin,et al.  NBEAL2 is mutated in Gray Platelet Syndrome and is required for biogenesis of platelet alpha-granules , 2011, Nature Genetics.

[14]  C. Tifft,et al.  The NIH Undiagnosed Diseases Program: lessons learned. , 2011, JAMA.

[15]  J. Lingeman,et al.  Nephrocalcinosis: re-defined in the era of endourology , 2010, Urological Research.

[16]  E. Mallet,et al.  Infantile hypercalcemia and hypercalciuria: new insights into a vitamin D-dependent mechanism and response to ketoconazole treatment. , 2010, The Journal of pediatrics.

[17]  Daniel L. Koller,et al.  Common genetic determinants of vitamin D insufficiency: a genome-wide association study , 2010, The Lancet.

[18]  T. Knoll,et al.  Urolithiasis through the ages: data on more than 200,000 urinary stone analyses. , 2010, The Journal of urology.

[19]  M. Brandi,et al.  Idiopathic hypercalciuria and calcium renal stone disease: our cases. , 2009, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[20]  M. D. de Broe,et al.  Nephrocalcinosis: new insights into mechanisms and consequences. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  A. Trinchieri.  Epidemiology of urolithiasis: an update. , 2008, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[22]  N. Loh,et al.  Genetics of Hypercalciuric Nephrolithiasis , 2007, Annals of the New York Academy of Sciences.

[23]  G. Curhan.  Epidemiology of stone disease. , 2007, The Urologic clinics of North America.

[24]  Glenville Jones,et al.  Generation of a homology model for the human cytochrome P450, CYP24A1, and the testing of putative substrate binding residues by site-directed mutagenesis and enzyme activity studies. , 2007, Archives of biochemistry and biophysics.

[25]  R. Serda,et al.  Hybrid homology modeling and mutational analysis of cytochrome P450C24A1 (CYP24A1) of the Vitamin D pathway: insights into substrate specificity and membrane bound structure-function. , 2007, Archives of biochemistry and biophysics.

[26]  K. Inouye,et al.  METABOLISM OF 2α-PROPOXY-1α,25-DIHYDROXYVITAMIN D3 AND 2α-(3-HYDROXYPROPOXY)-1α,25-DIHYDROXYVITAMIN D3 BY HUMAN CYP27A1 AND CYP24A1 , 2005, Drug Metabolism and Disposition.

[27]  K. Inouye,et al.  Metabolism of A-ring diastereomers of 1α,25-dihydroxyvitamin D3 by CYP24A1 ☆ , 2004 .

[28]  N. Simmons,et al.  Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. , 2004, Clinical science.

[29]  M. Chiu,et al.  Rat cytochrome P450C24 (CYP24A1) and the role of F249 in substrate binding and catalytic activity. , 2004, Archives of biochemistry and biophysics.

[30]  D. Peehl,et al.  Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. , 2002, The Journal of urology.

[31]  W. Willett,et al.  Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. , 2001, Kidney international.

[32]  J. D. Lin,et al.  Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing's disease. , 2000, Endocrine journal.

[33]  K. Inouye,et al.  Metabolism of vitamin D3 by human CYP27A1. , 2000 .

[34]  F. Glorieux,et al.  Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. , 2000, Endocrinology.

[35]  T. Maeda,et al.  Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney. , 2000, The Journal of endocrinology.

[36]  A. Takashima.  Establishment of Fibroblast Cultures , 1998, Current protocols in cell biology.

[37]  E. Rimm,et al.  Family history and risk of kidney stones. , 1997, Journal of the American Society of Nephrology : JASN.

[38]  N. Horiuchi,et al.  Mouse Vitamin D-24-Hydroxylase: Molecular Cloning, Tissue Distribution, and Transcriptional Regulation by 1α,25-Dihydroxyvitamin D3. , 1997, Endocrinology.

[39]  Y. Ohyama,et al.  Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. , 1995, Journal of lipid research.

[40]  Y. Tashiro,et al.  Quantitative immunoelectron microscopic analysis of the localization and induction of 25-hydroxyvitamin D3 24-hydroxylase in rat kidney. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[41]  A. Trinchieri,et al.  Familial aggregation of renal calcium stone disease. , 1988, The Journal of urology.

[42]  A. Freemont,et al.  The osteodystrophy of hypervitaminosis D: a metabolic study. , 1986, The Quarterly journal of medicine.

[43]  H. DeLuca,et al.  Metabolism of vitamin D: current status. , 1976, The American journal of clinical nutrition.

[44]  A. Pearse,et al.  A comparative cytochemical and cytologic study of vitamin D induced nephrocalcinosis. , 1960, The American journal of pathology.

[45]  Liang Shen,et al.  CYP24A1 mutations in idiopathic infantile hypercalcemia. , 2011, The New England journal of medicine.

[46]  D. Assimos,et al.  Kidney stones: a global picture of prevalence, incidence, and associated risk factors. , 2010, Reviews in urology.

[47]  N. Kagawa,et al.  Metabolism of vitamin D3 by cytochromes P450. , 2005, Frontiers in bioscience : a journal and virtual library.

[48]  H. Morris,et al.  Vitamin D metabolism: new concepts and clinical implications. , 2003, The Clinical biochemist. Reviews.

[49]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[50]  R. Horst,et al.  Impaired 24,25-dihydroxyvitamin D production in anephric human and pig. , 1981, The Journal of clinical investigation.

[51]  H. DeLuca,et al.  Determination of stereochemical configuration of the 24-hydroxyl group of 24,25-dihydroxyvitamin D3 and its biological importance. , 1975, Archives of biochemistry and biophysics.